1-20 of 46
myeloproliferative disease
Close
Sort by
Journal Articles

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms

Brady L. Stein, Karlyn Martin
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 397–406.
https://doi.org/10.1182/hematology.2019001318
Published: 2019
Journal Articles

Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN

Aaron T. Gerds
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 407–414.
https://doi.org/10.1182/hematology.2019000048
Published: 2019
Journal Articles

JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy

Michele Ciboddo, Ann Mullally
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 110–117.
https://doi.org/10.1182/asheducation-2018.1.110
Published: 2018
Journal Articles

Myeloproliferative neoplasms: from origins to outcomes

Jyoti Nangalia, Anthony R. Green
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 470–479.
https://doi.org/10.1182/asheducation-2017.1.470
Published: 2017
Journal Articles

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Alessandro M. Vannucchi, Paola Guglielmelli
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 480–488.
https://doi.org/10.1182/asheducation-2017.1.480
Published: 2017
Journal Articles

Myelodysplastic and myeloproliferative disorders of childhood

Henrik Hasle
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 598–604.
https://doi.org/10.1182/asheducation-2016.1.598
Published: 2016
Journal Articles

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Naveen Pemmaraju, Ruben Mesa
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 649–651.
https://doi.org/10.1182/asheducation-2015.1.649
Published: 2015
Journal Articles

Management of symptoms in polycythemia vera and essential thrombocythemia patients

Deepti Radia, Holly L. Geyer
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 340–348.
https://doi.org/10.1182/asheducation-2015.1.340
Published: 2015
Journal Articles

Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?

Eric Padron
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 349–354.
https://doi.org/10.1182/asheducation-2015.1.349
Published: 2015
Journal Articles

Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis

John Mascarenhas
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 329–339.
https://doi.org/10.1182/asheducation-2015.1.329
Published: 2015
Journal Articles

Established and novel agents for myelodysplastic syndromes

Mikkael A. Sekeres, Aaron T. Gerds
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 82–89.
https://doi.org/10.1182/asheducation-2014.1.82
Published: 2014
Journal Articles

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Holly L. Geyer, Ruben A. Mesa
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 277–286.
https://doi.org/10.1182/asheducation-2014.1.277
Published: 2014
Journal Articles

The evolving genomic landscape of myeloproliferative neoplasms

Jyoti Nangalia, Tony R. Green
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 287–296.
https://doi.org/10.1182/asheducation-2014.1.287
Published: 2014
Journal Articles

Management of MPN beyond JAK2

Claire N. Harrison, Natalia Curto Garcia
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 348–354.
https://doi.org/10.1182/asheducation-2014.1.348
Published: 2014
Journal Articles

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

Edwin Chen, Ann Mullally
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 268–276.
https://doi.org/10.1182/asheducation-2014.1.268
Published: 2014
Journal Articles

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside

Jason Gotlib
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 529–537.
https://doi.org/10.1182/asheducation-2013.1.529
Published: 2013
Journal Articles

Focus on the epigenome in the myeloproliferative neoplasms

Eunhee Kim, Omar Abdel-Wahab
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 538–544.
https://doi.org/10.1182/asheducation-2013.1.538
Published: 2013
Journal Articles

Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?

Stefan N. Constantinescu, William Vainchenker
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 553–560.
https://doi.org/10.1182/asheducation.V2012.1.553.3800163
Published: 2012
Journal Articles

The spectrum of JAK2-positive myeloproliferative neoplasms

Jean-Jacques Kiladjian
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 561–566.
https://doi.org/10.1182/asheducation.V2012.1.561.3807838
Published: 2012
Journal Articles

Thrombotic disease in the myeloproliferative neoplasms

Anna Falanga, Marina Marchetti
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 571–581.
https://doi.org/10.1182/asheducation.V2012.1.571.3798557
Published: 2012